HC Wainwright Forecasts Palisade Bio Q1 Earnings

Palisade Bio, Inc. (NASDAQ:PALI) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Palisade Bio in a research report issued on Thursday, March 26th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. HC Wainwright also issued estimates for Palisade Bio’s Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.02) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.12) EPS.

Other equities analysts have also issued reports about the stock. B. Riley Financial began coverage on shares of Palisade Bio in a research report on Friday, January 9th. They set a “buy” rating and a $7.00 price target on the stock. Piper Sandler assumed coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 target price on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Stifel Nicolaus began coverage on Palisade Bio in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Clear Str raised Palisade Bio to a “strong-buy” rating in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $2.00 on Monday. The firm has a 50-day simple moving average of $1.78 and a 200-day simple moving average of $1.76. The stock has a market capitalization of $331.76 million, a price-to-earnings ratio of -0.94 and a beta of 1.53. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.64.

Hedge Funds Weigh In On Palisade Bio

A number of institutional investors have recently bought and sold shares of PALI. Total Clarity Wealth Management Inc. acquired a new position in Palisade Bio in the 4th quarter valued at about $70,000. Jefferies Financial Group Inc. purchased a new stake in shares of Palisade Bio during the 4th quarter valued at approximately $110,000. Geode Capital Management LLC lifted its holdings in Palisade Bio by 5,780.7% in the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after acquiring an additional 1,538,832 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Palisade Bio in the fourth quarter valued at approximately $1,310,000. Finally, TD Asset Management Inc acquired a new position in Palisade Bio in the fourth quarter valued at approximately $480,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

More Palisade Bio News

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $7.00 price target — a material upside vs. the current share price that can attract buyer interest and improve sentiment. Palisade Bio (NASDAQ:PALI) Research Coverage Started at HC Wainwright
• Neutral Sentiment: HC Wainwright published detailed EPS forecasts: quarterly losses in the range of roughly ($0.01)–($0.03) through FY2027 and an FY2027 EPS forecast of about ($0.12). These projected small per-quarter losses suggest the analyst model anticipates limited near-term burn per share, but results will hinge on clinical and business execution. MarketBeat PALI coverage summary
• Negative Sentiment: Palisade remains unprofitable; continued negative EPS implies potential future financing/dilution and exposes the stock to clinical and regulatory binary risks common to biotech names — these are key downside factors for investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.